Up-regulation of SOCS4 promotes cell proliferation and migration in esophageal squamous cell carcinoma.

BACKGROUND: Suppressors of cytokine signaling family member 4 (SOCS4) was shown to serve critical and multifaceted roles in the progression of numerous cancers, including hepatocellular carcinoma, thyroid cancer, breast cancer, and lung adenocarcinoma. While, the expression and the roles of SOCS4 in esophageal squamous cell carcinoma (ESCC) remain elusive. The current study is aimed to investigate the expression pattern and functions of SOCS4 in ESCC.
METHODS: The relationship between SOCS4 and the clinicopathological features of ESCC was analyzed. SOCS4 expression in ESCC tissues was measured by western blot, quantitative real-time polymerase chain reaction (qRT-PCR), and immunohistochemical (IHC) staining. The roles of SOCS4 in modulating ESCC cell behaviors were examined using a series of assays, including cell proliferation assay, cell counting kit-8 (CCK-8) assay, cell cycle analysis, and wound-healing assay.
RESULTS: In human ESCC tissues, SOCS4 expression was up-regulated and correlated with tumor size and lymph node metastasis, however was not correlated with the overall survival (OS) of patients. SOCS4 silencing in ESCC cells resulted in the suppression of cell growth, which was related to the cell cycle. SOCS4 knockdown also inhibited nuclear factor-kappa B (NF-κB) signaling and decreased the migratory potential of ESCC cells.
CONCLUSIONS: These findings revealed that increased expression of SOCS4 in ESCC may promote the progression, proliferation, and migration by NF-κB signaling. Inhibition of SOCS4 may be a promising therapeutic strategy for ESCC. 2021 Translational Cancer Research. All rights reserved.

Introduction

Esophageal cancer (EC) is the sixth most common malignancy worldwide (1), with esophageal squamous cell carcinoma (ESCC) accounting for ~90% of ECs (1). Despite improvements in ESCC treatments in recent years, the cure rate of ESCC is still low (2,3). Most ESCC is diagnosed at advanced stage, which makes treatments more difficult and less effective (4). Unfortunately, the mechanism underlying ESCC metastasis remains unknown. Therefore, studies are needed to identify the proteins that play critical roles in regulating the metastasis of ESCC, which is essential for improving early detection and the discovery of novel therapeutic targets.

Suppressors of cytokine signaling (SOCS) family proteins are negative modulators of cytokine and growth factor signaling. The SOCS family consists of eight members, including SOCS1–SOCS7 and cytokine-induced signal transducer and activator of transcription (STAT) inhibitor (CIS) (5,6). The loss or down-regulation of SOCS proteins has been shown to lead to many diseases, including cancer. In the SOCS family, SOCS1 and SOCS3 have been reported in different cancers, including gastric cancer (7), laryngeal carcinoma (8), hepatocellular carcinoma (9), melanoma (10), and breast cancer (11-13). Recently, the down-regulation of SOCS4 was shown to serve critical and multifaceted roles in the progression of numerous cancers, including hepatocellular carcinoma (14), thyroid cancer (15), breast cancer, and lung adenocarcinoma (16). These findings indicate that SOCS4 may be an attractive therapeutic target in cancer treatment. While, the expression and the roles of SOCS4 in ESCC remain elusive.

In the current report, the expression of SOCS4 in ESCC was detected, and the relationship between SOCS4 expression and the clinicopathological features of ESCC was investigated. Moreover, the roles of SOCS4 on the proliferation and migration of ESCC cells were also investigated.

We present the following article in accordance with the MDAR reporting checklist (available at http://dx.doi.org/10.21037/tcr-21-700).

Methods

Bioinformatic analysis

The datasets in The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/) were used to examine the expression pattern of SOCS4 in ESCC. Briefly, we used GEPIA (Gene Expression Profiling Interactive Analysis, http://gepia.cancer-pku.cn/index.html), which is a web-based tool, to perform the differential gene analysis (tumor: n=182; normal: n=286) in TCGA.

Patients and tissue samples

A total of 103 ESCC tissues and non-carcinoma tissues were obtained from the Affiliated Nanjing Hospital of Nanjing Medical University. All patients underwent surgery between July 2006 and December 2008, and did not receive any anti-tumor therapy prior to surgery. The overall survival (OS) of patients denotes the months from diagnosis until the date of death, last known to be alive, or the study closing date. The clinicopathological parameters of the patients are shown in . This study was approved by the Ethics Committee of People’s Hospital of Xuyi (No. XYLL-2018006). All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). Informed consent was taken from all the patients.

Table 1

Clinical specimens of patients with ESCC

Variables	Patient (n=103)
Age (y ± SD)	65.2±9.3
Sex (female: male)	28:75
Tumor size
<5 cm	59
≥5 cm	44
Pathological grade
Poor	8
Moderately	67
Well	28
Lymph node (LN) metastasis
Yes	38
No	65

ESCC, esophageal squamous cell carcinoma.

Immunohistochemical (IHC) staining

For immunohistochemistry, paraffin sections were deparaffinised, and then rehydrated with graded ethyl alcohol. Hydrogen peroxide (3%) was used to block endogenous peroxidase activity. A sodium citrate buffer was used to retrieve the antigens. A rabbit polyclonal antibody targeting SOCS4 (cat. No. PA5-21599; 1:1,000 dilution; Thermo Fisher Scientific™ Invitrogen, USA) was incubated at 4 °C overnight, and a horseradish peroxidase (HRP)-conjugated anti-rabbit immunoglobulin G (IgG) (cat. No. ab6721, 1:1,000 dilution, Abcam) was incubated at room temperature for 1 h. The slides were then developed with diaminobenzidine (DAB) (Beyotime Institute of Biotechnology, Haimen, China) for 5 min at room temperature. Images were captured under a light microscope (Olympus Corporation, Tokyo, Japan).

The stains were evaluated separately by two pathologists under double-blinded conditions and scored by staining intensity and positive staining. Staining intensity was graded as negative (0 point), weak (1 point), moderate (2 points), or strong (3 points). Positive staining was quantified and classified into five categories scored 0 to 4: <10% positive cells as 0; 10–25% as 1; 26–50% as 2; 51–75% as 3, and ≥76% as 4. The final score was calculated as the staining intensity score multiplied by the positive staining score. For categorical analyses, final scores of expression levels greater than 4 (final score >4) were regarded as high.

Cell culture

Eca-109 (human ESCC cell line) was obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and was cultured in RPMI 1640 medium (Gibco, Thermo Fisher Scientific™, USA) supplemented with 10% foetal bovine serum (YEASEN, Shanghai, China) and 100 U/mL penicillin/streptomycin (Gibco, Thermo Fisher Scientific™, USA) in 5% CO2 incubator at 37 °C.

siRNA transfection

The siRNA of SOCS4 was designed by the Shanghai China, GenePharma Co., Ltd., and the siRNA sequences are listed in . The siRNA was transfected into Eca109 cells using Lipofectamine RNA iMAX (Thermo Fisher Scientific™, USA) according to the manufacturer’s instructions. The cells were harvested 48–72 h after transfection and analyzed by quantitative real-time polymerase chain reaction (RT-qPCR) and western blotting.

Table 2

SOCS4 expression between ESCC tissue and non-carcinoma tissues

Tissue	SOCS4 expression level		P value
	High	Low
ESCC tissue	56	47	<0.001
Non-carcinoma tissues	17	49

ESCC, esophageal squamous cell carcinoma.

Cell proliferation assay

After siRNA transfection for 48 h, the cells were harvested and seeded in 6 cm dishes (1×104 cells/dish). The cell number was then counted every 24 h for a total of 5 days. A cell growth curve, expressed as the fold change in cell growth, was created using GraphPad Prism 5 (GraphPad software, Inc., USA).

Cell counting kit-8 (CCK-8) assay

A CCK-8 assay was used to measure cell viability. After siRNA transfection for 48 h, the cells were seeded in 96-well plates triplicatedly (1.0×104 cells/mL). After 24 h, cell viability was measured using CCK-8 (Nanjing KeyGen Biotech Co., Ltd. China) according to the manufacturer’s instructions. The absorbance was measured at 450 nm using a microplate reader (Multiskan FC, Thermo, USA), and the data was recorded every 24 h for 5 consecutive days.

Cell cycle analysis

After siRNA transfection, the cells were cultured in a serum-free medium for 24 h to synchronize at the G0/G1 phase, and cells were centrifugated (500 g ×5 min). After washing with phosphate buffered saline (PBS) three times, the cells were fixed with 70% ethanol at 4 °C overnight. Subsequently, the cells were washed with ice-cold PBS twice, and treated with RNA enzyme A (RNase A) (20 µg/mL of final concentration) and propidium iodide (10 µg/mL of final concentration) in the dark for 1 h at room temperature. The cell populations at the G0/G1, S, and G2/M phases were measured by flow cytometry (Navios, Thermo Fisher Scientific™, USA), and quantified using Kaluza Analysis software (Thermo Fisher Scientific™, USA). The assay was conducted triplicatedly.

Wound-healing assay

Cell migration ability was examined as previously reported (17). Briefly, the cells were seeded in 6-well plates until they reached confluence, and were then scratched using a 200-µL pipette tip. The gap was measured at 0 h (w1) and at 24 h (w2), respectively, and the relative migration rate was calculated as (w1−w2)/w1 ×100%. The wounds were photographed using a light microscope at a magnification of 100× (CKX53, OLYMPUS, Japan). The assay was conducted triplicatedly.

RNA extraction and quantitative RT-PCR

Total RNA was extracted using the Ultrapure RNA Kit (CWBIO, Beijing, China) according to the manufacturer’s instructions. Next, complementary DNA (cDNA) was synthesized using the 5× All-In-One Master Mix with AccuRT genomic DNA Removal Kit (abm®, Canada; catalog G492). Subsequently, quantitative PCR was performed using BrightGreen 2× qPCR Master Mix-ROX (abm®, Canada; catalog Master Mix-R) with the ABI StepOne Plus (Thermo Fisher ScientificTM, USA). The reaction conditions were as follows: 95 °C 10 min, 95 °C 15 s, and 60 °C 1 min for 40 cycles. The relative quantitative SOCS4 expression value was normalized to that of glyceraldehydes-3-phosphate dehydrogenase (GAPDH) and calculated using the 2-∆∆CT method. Each sample was examined in triplicate. The primers were designed as follows: SOCS4 forward, 5'-CATGGCAGAAAATAATGAAAATAT-3' and reverse, 5'-GTTTAAGAGATCGGCCTAAAAAT-3'; and GAPDH forward, 5'-ACCACAGTCCATGCCATCAC-3' and reverse, 5'-TCCACCACCCTGTTGCTGTA-3'.

Western blot

Cells were lysed in a radio immunoprecipitation assay (RIPA) buffer (Beyotime, China) supplemented with Complete Protease Inhibitor Cocktail (Roche, Germany) plus 1 mM phenylmethanesulfonyl fluoride (PMSF). For tissues, total protein was extracted from ESCC tissues and matched non-carcinoma tissues in 2% sodium dodecyl sulfate (SDS) in Nonidet P-40 (NP-40) lysate buffer, and then boiled at 98 °C for 10 min. After centrifugation (18,000 g ×15 min) at 4 °C, the supernatant was collected for use. Protein concentrations were measured using a BCA Kit (Beyotime, China). Next, 30 µg protein was electrophoresed through a 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto polyvinylidene fluoride (PVDF)membranes (Millipore, USA). After blocking with 5% milk, the membranes were immunoprobed with primary antibody at 4 °C overnight. After washing, the membranes were incubated with HRP-conjugated secondary antibody (Proteintech, USA) at room temperature for 1 h. After washing, the membranes were developed using an enhanced ECL kit (Beyotime, China), and the image was detected using a Clinx imaging system (Clinx Science Instruments, Co., Ltd., China). The primary antibodies were as follows: anti-SOCS4 antibody (1:1,000; Thermo Fisher Scientific™ Invitrogen, USA; catalog PA5-21599), anti-ICAM1 antibody (1:1,000; Cell Signaling Technology, USA; catalog #4915), anti-VCAM1 antibody (Cell Signaling Technology, USA; catalog #39236), anti-uPA antibody (1:1,000; Cell Signaling Technology, USA; catalog #67589), anti-TNF-α antibody (1:2,000; Cell Signaling Technology, USA; catalog #6945), anti-NF-κB p65 antibody (1:2,000; Cell Signaling Technology, USA; catalog #8242), anti-phospho-NF-κB p65 antibody (1:2,000; Cell Signaling Technology, USA; catalog #3033), and anti-β-actin antibody (1:3,000; Sigma-Aldrich, Japan; catalog A1978).

Statistical analysis

The data were analysed using SPSS 25.0 (SPSS, Inc., Chicago, IL, USA). All data were recorded as the mean ± SD or n/%. The differences in the expression of SOCS4 between tumour tissues and non-carcinoma tissues were analysed using Chi-square analysis. The correlations between SOCS4 expression and the clinicopathological parameters of ESCC were analysed using Pearson’s chi-squared test. Survival curves were generated using the Kaplan-Meier method and analyzed by log-rank test. The Student’s t-test was used to determine the differences between two groups. One-way analysis of variance (ANOVA) was used to analyze the differences between multiple groups. All experiments were performed at least three times, and P<0.05 was considered statistically significant.

Results

Upregulatedexpression of SOCS4 in human ESCC tissues

First, SOCS4 expression was analyzed in human ESCC tissues. SOCS4 mRNA was significantly upregulated in ESCC tissues compared to adjacent normal tissues (). A total of 5 independent ESCC tissues were then analyzed, and the results showed that the expression levels of the SOCS4 protein in ESCC tissues was significantly higher than that in adjacent normal tissues ().

Figure 1

SOCS4 expression was up-regulated in ESCC tissues. SOCS4 mRNA (A) expressions in ESCC tissue and normal tissues in TCGA database (A), SOCS4 protein expressions in ESCC tissue (T) and normal tissues (N) were measured using western blotting (B). *, P<0.05, compared with normal tissues. SOCS4, suppressors of cytokine signaling family member 4; ESCC, esophageal squamous cell carcinoma.

Next, immunohistochemistry was used to further measure the expression of SOCS4 in 103 ESCC tissues. In the ESCC tissues, SOCS4 was mostly expressed in the cytoplasm (). Moreover, in ESCC tissues, the positive expression of SOCS4 was 54.4% (56/103), and was only 25.7% (17/66) in the adjacent normal tissues ().

Figure 2

SOCS4 expression in ESCC tissues and adjacent normal tissues by immunohistochemistry. Representative immunostaining of SOCS4 in human ESCC tissues (A,B) and adjacent normal tissues (C,D), magnification 40× (A,C), magnification 200× (B,D). SOCS4, suppressors of cytokine signaling family member 4; ESCC, esophageal squamous cell carcinoma, Scale bar: 50 µm.

Correlations between SOCS4 expression and the clinicopathological features of ESCC

The correlations between SOCS4 expression and the clinicopathological features of ESCC were analyzed. We found that SOCS4 expression was not associated withage, gender, or pathological grade of ESCC. The high-expression of SOCS4 was positively correlated with tumor size and lymph node metastasis (). Kaplan-Meier survival analysis revealed that ESCC patients with a high SOCS4 expression had a similar OS compared to those with a low SOCS4 expression ().

Table 3

Correlations between SOCS4 expression and the clinicopathologic characteristics of ESCC patients

Characteristics	SOCS4 expression level		P value
	Low (%)	High (%)
All patients	47 (45.6)	56 (54.4)
Age (years)
<65	24 (46.2)	28 (53.8)	0.915
≥65	23 (45.1)	28 (54.9)
Gender
Male	35 (46.7)	40 (53.3)	0.733
Female	12 (42.9)	16 (57.1)
Tumor size
<5 cm	34 (57.6)	25 (42.4)	0.016
≥5 cm	13 (28.3)	31 (71.7)
Pathological grade
Poor	4 (50.0)	4 (50.0)	0.695
Moderately	31 (46.3)	36 (53.7)
Well	12 (42.9)	16 (57.1)
Lymph node metastasis
Yes	7 (18.4)	31 (81.6)	0.006
No	40 (61.5)	25 (38.5)

SOCS4, suppressors of cytokine signalling family member 4; ESCC, esophageal squamous cell carcinoma.

Figure 3

Kaplan-Meier survival curves of ESCC patients with a high SOCS4 expression (n=56) had a similar OS compared to those with a low SOCS4 expression (n=47). P>0.05. SOCS4, suppressors of cytokine signaling family member 4; ESCC, esophageal squamous cell carcinoma.

Knockdown of SOCS4 inhibits the proliferation of ESCC cells in vitro

In order to determine whether SOCS4 plays a vital role in ESCC cell behaviors, SOCS4 was knowdowned by siRNA in Eca109 cells. The expression of SOCS4 mRNA () and protein () were successfully decreased in Eca109 cells compared with the control siRNA-transfected cells. Our results showed that SOCS4 knockdown reduced the growth of Eca109 cells when assessed daily over a 5-day period (), and also decreased cell viability in the CCK-8 assay ().

Figure 4

SOCS4 knockdown inhibits ESCC cell proliferation. SOCS4 expression in Eca-109 cells following transfection with control siRNA (Si-ctrl), SOCS4 siRNAs (Si-SOCS4-1 and Si-SOCS4-1) were measured by RT-qPCR (A) and western blot (B), respectively. The effect of SOCS4 knockdown on cell proliferation. Eca-109 cells transiently transfected with Si-ctrl, Si-SOCS4-1, and Si-SOCS4-1 were cultured for 72 h. Cell growth was measured by counting cell numbers (C,D), and cell viability was measured using an CCK-8 assay. The effect of SOCS4 knockdown on cell cycle was measured by flow cytometry (E). ***, P<0.001, compared with Si-ctrl. SOCS4, suppressors of cytokine signaling family member 4; ESCC, esophageal squamous cell carcinoma.

Next, the cell cycle was detected by flow cytometry. SOCS4 knockdown resulted ina decrease in the percentage of G0/G1 phase cells from 55.38% to 42.23% (Si-SOCS4-1) or 45.37% (Si-SOCS4-2), and an increase in the percentage G2/M phase cells from 29.07% to 41.02% (Si-SOCS4-1) or 39.46% (Si-SOCS4-2) ().

Knockdown of SOCS4 inhibits the migration of ESCC cells in vitro

A wound healing assay was performed. The results showed that SOCS4 knockdown in Eca109 cells significantly inhibited cell migration compared with control cells ().

Figure 5

SOCS4 knockdown inhibits ESCC cell migration. (A,B) Effects of SOCS4 knockdown on cell migration. Eca-109 cells transfected with control siRNA (Si-ctrl) or SOCS4 siRNAs (Si-SOCS4-1 and Si-SOCS4-1) were subjected to a wound closure assay. ***, P<0.001, compared with Si-ctrl (100×). SOCS4, suppressors of cytokine signaling family member 4; ESCC, esophageal squamous cell carcinoma.

Knockdown of SOCS4 inhibits NF-κB signaling in ESCC cells

It has been well documented that NF-κB signaling is critical for ESCC cell proliferation and migration. The expression level of NF-κB p65 was also quantified by western blotting as shown in , the phosphorylated levels of p65 were down-regulated by SOCS4 knockdown, however the total p65 level was unaffected. Moreover, several NF-κB-regulated metastasis-related genes, including intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM1), urokinase-type plasminogen activator (uPA), and tumor necrosis factor (TNF-α), were markedly decreased in SOCS4-knockdown ESCC cells.

Figure 6

SOCS4 knockdown inhibits NF-κB signaling. Eca-109 cells were transfected with control siRNA (Si-ctrl) or SOCS4 siRNAs (Si-SOCS4-1 and Si-SOCS4-1), and then the cells were prepared for immunoblotting against p-P65, P65, ICAM1, VCAM1, uPA, and TNFα. β-actin was used as an internal loading control. **, P<0.001, compared with Si-ctrl. SOCS4, suppressors of cytokine signaling family member 4.

Discussion

SOCS proteins play important roles in the progression of various tumors (18-21). SOCS4, a major member of the SOCS family, negatively regulates cell signal transduction. Cumulative studies have demonstrated that SOCS4is critical for the progression of multiple types of cancers, including breast cancer (13,22), lung adenocarcinoma (16,23), endometrial carcinoma (24), gastric cancer (25,26), and hepatic carcinoma (27). However, the expression and actual biological functions of SOCS4 in ESCC remain elusive. The current study investigated the expression and functions of SOCS4 in ESCC, which may provide potential implications for ESCC therapy.

In this study, the clinical significance of SOCS4 in ESCC was investigated for the first time. SOCS4 was found to be up-regulated in human ESCC tissues, which was associated with tumor size and lymph node metastasis. These findings indicated that SOCS4 might play a pro-tumor role in ESCC.

Previous studies have reported that SOCS4 is involved in several important processes, including cell migration, proliferation, invasion, and the stemness maintenance of cancer stem cells (14-16). In the current study, we found that the knockdown of SOCS4 could reduce the migration capacity of Eca109 cells. Furthermore, the suppression of SOCS4 reduced the proliferation of Eca109 cells along with cell accumulation in the G2/M phase. These results indicated that SOCS4 promoted cell proliferation and migration in ESCC cells.

The above findings were different from the previous findings on other cancer cells, which showed that SOCS4 is down-regulated in gastric cancer, hepatic carcinoma, breast cancer, and lung adenocarcinoma, and acted as a tumor suppressor in these cancers, inhibiting the proliferation, migration, and invasion of cancer cells (14-16). This discrepancy between our results and these previous findings suggests that the effects of SOCS4 on the malignant behaviors of cancer cells may be cell-type dependent on the heterogeneity of SOCS4, or its interaction with distinct substrates or binding partners.

In addition, we further explored the underlying mechanism. We found that SOCS4 silencing markedly inhibited phosphorylated levels of NF-κB p65 as well as NF-κB-regulated metastasis-related genes, including ICAM1, VCAM1, uPA, and TNFα, suggesting that NF-κB signaling was regulated by SOCS4 in ESCC cells. NF-κB signaling is critical for proliferation and migration in numerous cancer cell types, including ESCC cells (28-30). Therefore, it is reasonable to speculate that the decreased proliferation and migration observed in SOCS4-knockdown Eca109 cells is due to the inactivation of NF-κB signaling. A previous study showed that NF-κB activity was negatively regulated by SOCS4 in IPEC-J2 cells (31), which was contrary to our results. This suggested that the effect of SOCS4 on NF-κB activity depends on cell type. In future research, it will be important to investigate the mechanism through which SOCS4 regulates NF-κB activity in our system.

Previous studies have also demonstrated that SOCS4 inactivated the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) pathways, and therefore served as a tumor suppressor in several types of cancer cells (14-16). The PI3K/AKT pathway is activated in ESCC and impacts on various biological behaviors such as migration, invasion, proliferation, and apoptosis (32-35). The activation of the JAK/STAT3 pathway plays a critical role in the migration, invasion, and proliferation of ESCC (36-40). Based on these findings, we hypothesized that SOCS4 might promote the proliferation and migration of ESCC cells in a PI3K/AKT and JAK/STAT3 pathways-independent way, which needs to be investigated in the near future.

However, there are some limitations in the current study. First, more than one cell line should be used to investigate the role of SOCS4 on ESCC. Then, further study is needed to investigate the effect of SOCS4 on ESCC cell proliferation and migration in vivo, as well as its underlying mechanisms. Nest, it will also be important to investigate the role and underlying mechanisms of SOCS4 on other aspects of ESCC progression such as apoptosis. Finally, the expression pattern, functions, and molecular mechanism of SOCS4 in other types of cancer are also needed further investigated.

Conclusions

The current study revealed, for the first time, that the up-regulation of SOCS4 in ESCC was associated with tumor size and lymph node metastasis. SOCS4 knockdown in vitro inhibited the proliferation and migration of ESCC cells and NF-κB signaling, indicating that SOCS4 may be a novel potential therapeutic target for ESCC.